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ABSTRACT 
Introduction: Hypertension is the most common risk factor for heart failure causing an increase in N-Terminal-Pro Brain Natriuretic Peptide (NT-
proBNP) level and a decrease in left ventricular ejection fraction (LVEF). Objective: To investigate the effect of hypertension on NT-proBNP level and 
LVEF in patients with chronic heart failure.
Methods: This cross sectional study takes 29 people with hypertension stage-1 (HTD-1) and 27 people with hypertension stage-2 (HTD-2) as sample. 
The left ventricular ejection fraction and NT-proBNP level obtained from medical records are analyzed using independent t test and Mann Withney test, 
followed with Spearmen correlation between NT-proBNP level and LVEF.
Results: Mann-Whitney test indicates that the mean value of NT-proBNP level of HTD-2 is significantly higher compared to that of HTD-1, p = 0,000. 
On the contrary, the independent t test shows that LVEF in HTD-2 is lower than that of HDT-1, p = 0.001. The Spearman correlation analysis conducted 
on the NT-proBNP level and the LVEF results in value of -0.651, p = 0.000. The cut-off-point value of NT-proBNP level is 1511pg/ml (sensitivity 0.82% 
and specificity 0.80%) and the value of area under the ROC curve > 0.7. The left ventricular ejection fraction has an area under the ROC curve > 0.7 with 
a cut-off-point value of 39% (sensitivity 0.67% and specificity 0.69%).
Conclusion: The NT-proBNP level and the LVEF of HTD-2 are significant higher and lower respectively compared to those of HTD-1. The NT-proBNP 
level and LVEF also show a strong negative correlation. The cut-off-point value of NT-proBNP level and LVEF can be utilized to compare the stages of 
hypertension in patients with chronic heart failure.
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ABSTRAK
Pendahuluan: Hipertensi merupakan faktor resiko tersering pada gagal jantung yang menyebabkan peningkatan kadar N-Terminal-Pro 
Brain Natriuretic Peptide (NT-proBNP) dan penurunan fraksi ejeksi ventrikel kiri (FEVK). Tujuan: Untuk mengetahui pengaruh derajat 
hipertensi terhadap kadar NT-proBNP dan FEVK pada pasien gagal jantung kronik. 
Metode: Penelitian observasional ini menggunakan rancangan cross sectional study. Sampel penelitian terdiri dari 29 orang dengan 
hipertensi derajat 1 (HTD-1) dan 27 orang dengan hipertensi derajat 2 (HTD-2) yang telah memenuhi kriteria inklusi. Data FEVK  dan 
kadar NT-proBNP diperoleh dari rekam medis, masing-masing dianalisis dengan independent t test dan Mann Withney test. Korelasi 
antara kadar NT-proBNP dengan FEVK dianalisis dengan korelasi Spearman.
Hasil: Hasil uji Mann-Whitney menunjukkan bahwa rerata kadar NT-proBNP HTD-2 lebih tinggi bermakna disbanding HTD-1, p<0.01. 
Hasil independent t test menunjukkan bahwa FEVK pada HTD-2 lebih rendah dibanding HTD-1, p<0.05. Hasil uji korelasi Spearman 
antara kadar NT-proBNP dengan FEVK sebesar -0,651, p=0,000. Nilai cut-off-point kadar NT-proBNP didapatkan sebesar 1511pg/ml 
(sensitivitas 0,82% dan spesifitas 0,80%) dan nilai luas area dibawah kurva ROC>0,7. Fraksi ejeksi ventrikel kiri memiliki luas area 
bawah kurva ROC>0,7 dengan nilai cut-off-point sebesar 39% (sensitivitas 0,67% dan spesifitas 0,69%). 
Kesimpulan: Kadar NT-proBNP pada HTD-2 dengan gagal jantung kronik lebih tinggi, sedangkan FEVK lebih rendah dibanding 
HTD-1. Terdapat korelasi negatif yang kuat antara kadar NT-proBNP dengan FEVK. Nilai cut-off-point kadar NT-proBNP dan FEVK 
dapat digunakan untuk membandingkan derajat hipertensi pada pasien gagal jantung kronik.
Kata kunci: Derajat hipertensi, NT-proBNP, fraksi ejeksi ventrikel kiri, gagal jantung kronik.
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INTRODUCTION
Heart failure is a complex clinical syndrome 
with a sign of  heart’s decreasing capability of  pumping 
blood (Tan et al., 2010). Physiologically, heart failure 
is defined as inadequate cardiac output to fulfill body’s 
metabolic needs. Epidemiologically, heart failure 
becomes pandemic, considering that 26 million people 
throughout the world have this disease (Savarese and 
Lund, 2017). In Indonesia, according to the data of  
RISKESDAS in 2013, the prevalence of  heart failure 
is expected to be 0.13% (229,696 people) with the 
estimated highest number is of  West Java Province 
of  96,487 people (PERKI, 2015). Hypertension is the 
most risk factor to cause heart failure as marked with 
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an increase in N-terminal pro-Brain Natriuretic Peptide 
(NT-proBNP) (Weber et al., 2006). According to The 
Seventh Report of  The Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of  
High Blood Pressure (JNC VII), hypertension is divided 
into normal, pre-hypertension, hypertension stage 1, 
and hypertension stage 2 which may potentially cause 
heart failure and reduce left ventricular ejection fraction. 
In line with ejection fraction, natriuretic peptide level, 
heart structural change, and diastolic dysfunction, heart 
failure is divided into three: heart failure with a decrease 
of  ejection fraction, heart failure with maintained 
ejection fraction, and heart failure with ejection fraction 
between both (Ponikowski et al., 2016).
Various evidences show that NT-proBNP is 
peptide produced by cardiac myocytes as a response 
to mechanical stretch, oxidative stress, myocardial 
hypoxia, and toxicity (Drewniak et al., 2015; McKie and 
Burnett, 2016; Vanderheyden et al., 2004). Therefore, 
NT-proBNP level will increase in case of  pressure and 
damage to cardiac myocytes, which may be taken as an 
important sign of  heart failure because of  various causes, 
including hypertension (McKie and Burnett, 2016; 
Nadir et al., 2012). The study reported by Drewniak W, 
et al. shows that NT-proBNP level with heart failure 
is significantly higher than that without heart failure 
(Drewniak et al., 2015). Moreover, an increase in NT-
proBNP because of  hypertension or any other causes is 
also followed with a decrease of  left ventricular ejection 
fraction (Volpe et al., 2016b). However, the value of  NT-
proBNP and left ventricular ejection fraction (FEVK) to 
be taken to distinguish hypertension stages in chronic 
heart failure is unknown. 
The NT-proBNP level and left ventricular 
ejection fraction in asymptomatic hypertension, 
hypertension with breathlessness during exercise, and 
hypertension with heart failure patients are different. 
The higher the NT-proBNP level, the lower the ejection 
fraction in hypertension patient with various clinical 
manifestations is (Bielecka-dabrowa et al., 2015b). An 
increase in NT-proBNP level because of  hypertension 
is caused by increasing pressure and volume of  left 
ventricular wall, causing left ventricular wall stress. 
This left ventricular wall stress will stimulate synthesis 
and secretion of  Brain Natriuretic Peptide (BNP; 
active) and NT-proBNP (inactive) in cardiomyocytes 
cells. Hypertension also causes a release of  Renin-
Angiotensin-Aldosterone System (RAAS), sympathetic 
nervous system (SNS), endothelin, Reactive Oxygen 
Species (ROS), inflammation factor (TNF-α and IL-
6) and myocardial hypoxia, which will increase quick 
release of  NT-proBNP. An increase in RAAS, SNS, 
endothelin, ROS, TNF-α and IL-6, and NT-proBNP 
will cause heart structural and functional changes 
like cardiac remodeling, left ventricular hypertrophy, 
and left ventricular diastolic dysfunction and systolic 
dysfunction. This will increase the progression of  heart 
failure (Volpe et al., 2016a, 2016b). 
 The purpose of  this research is to examine the 
effect of  hypertension stage on NT-proBNP level and 
FEVK in chronic heart failure, expected to be utilized 
as the cornerstone to detect the progress of  chronic 
heart failure and to prevent prognosis from worsening in 
chronic heart failure because of  hypertension stage.
METHODS
In the cross sectional design, 56 patients’ 
medical records from January 2016 to August 2018 
are taken from Heart Clinic, Cirebon as samples. 
The samples are classified into chronic heart failure 
with hypertension stage 1 (HTD-1) and chronic 
heart failure with hypertension stage 2 (HTD-2). The 
samples meet the inclusion criteria: chronic heart failure 
patients with hypertension and complete medical 
record data. The chronic heart failure patients with 
hypertension and other risk factors such as diabetes 
mellitus, hypercholesterolemia, hypertriglyceridemia 
and decreased kidney function are excluded. The 
blood pressure, are, sex, one-time blood sugar, total 
cholesterol, triglyceride, urea, creatinine, NT-proBNP, 
and left ventricular ejection fraction data collected 
from patients’ medical record data. This research is 
conducted in Heart Clinic, Cirebon upon approval 
of  the ethics commission of  the Faculty of  Medicine, 
Unissula Semarang under No. 325/IX/2018/Komisi 
Bioetik.
Research Variables Measurement
All of  the data are collected from medical records 
consisting of  blood pressure, NT-proBNP, and left 
ventricular ejection fraction. Blood pressure is measured 
using mercury manometer, while NT-proBNP level 
is diagnosed using ELECSYS 2010 analyzer (Roche 
Diagnostic) on venous blood and left ventricular 
ejection fraction is diagnosed using echocardiogram 
and interpreted by a cardiovascular specialist. 
Statistical Analysis 
The data collected are tested for their normality 
using Shapiro-Wilk test, and homogeneity using Levene’s 
test. The difference in NT-proBNP level is tested using 
Mann Withney, while in left ventricular ejection fraction 
is tested using independent t-test statistical analysis. 
The correlation between NT-proBNP level and left 
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ventricular ejection fraction is tested using Spearman 
test. The cut-off-point of  NT-proBNP level and left 
ventricular ejection fraction of  each hypertension stage 
is assessed using Receiver Operating Curve (ROC) 
analysis. The statistical calculation employs Statistical 
Package for Social Science (SPSS) Software. The 
analysis results will be considered significant if  the 
value p<0.05.
RESULTS
The 56 samples meet the inclusion and exclusion 
criteria, consisting of  29 patients of  chronic heart 
failure with hypertension stage 1 (HTD-1) group and 27 
patients of  chronic heart failure with hypertension stage 
2 (HTD-2) group, with patients’ basic characteristics 
of  both groups are presented in Table 1. 
The sex, mean age, one-time blood sugar level, 
total cholesterol, triglyceride, urea, and creatinine 
variables are insignificantly different between the 
HTD-1 and HTD-2 groups of  heart failure patients. 
Therefore, the research samples of  both groups are 
comparable. The results of  examination of  NT-pro 
BNP level and FEVK of  sample medical records are 
as listed in table 2. 
The examination results show that the NT-
proBNP level of  HTD-2 group is higher than that 
of  HTD-1 group. On the contrary, the FEVK of  
HTD-2 group is lower than that of  HTD-1 group. 
whether the difference is significant. Considering that 
the normality and homogeneity tests conducted to the 
NT-proBNP level show abnormally distributed and non-
homogenous data, a Mann-Whitney test is conducted 
for the difference in the NT-proBNP levels of  both 
groups. The Mann-Whitney test results show that the 
NT-proBNP level of  HTD-2 group is higher than that 
of  HTD-1 group, p< 0.05 (figure 1). On the contrary, 
for the difference in FEVK, an independent T test is 
conducted considering the normally distributed and 
homogenous data. The independent T test results show 
that the FEVK of  HTD-2 group is significantly lower 
than that of  HTD-1 group, p < 0.05 (figure 2).
The examination results of  NT-proBNP level 
and FEVK in HTD-2 group show high NT-proBNP, 
followed with low FEVK. On the contrary, low NT-
proBNP level is followed with high FEVK. A Spearman 
correlation test needs to be conducted to find out 
whether NT-proBNP level is negatively correlated with 
left ventricular ejection fraction level. The statistical 
test results show strong negative correlation of  0.651, 
p < 0.001 (Figure 2).
Moreover, the Cut-off-point of  NT-proBNP level 
has area under ROC curve>0.7 of  0.844 (95% CI=0.743 
to 0.944) and p value = 0.000, showing that this NT-
proBNP level may be taken to distinguish hypertension 
stages in chronic heart failure. The Cut-off-point of  NT-
proBNP level based on the ROC curve analysis is 1511 
pg/ml with sensitivity of  0.82% and specificity of  0.80% A statistical test needs to be conducted to find out 
Table 1. Baseline Data of Research Samples
Note:  Age, one-time blood sugar, total cholesterol, triglyceride, urea, and creatinine are given in 
mean. Sex and blood pressure are given in proportion. Tests used: (a) Fisher Exact test, (b) independent 
t test, and (c) Mann-Whitney Test.  The data above is based on patients’ medical records.
Table 2. Mean of NT-proBNP Level and Left Ventricular Ejection Fraction
Note: * Levene test; ** Shapiro Wilk




n = 29, (x±SD) 
HTD-2 
n = 27, (x±SD) 
p value 
Men/Women 14/15 18/9 0.19 (a) 
Age (years) 57.38 ± 13.67 62.70 ± 11.29 0.12(b) 
One-Time Blood Sugar (mg/dl)  138.21 ± 30.330 133.11 ± 31.58 0.54(b) 
Total Cholesterol (mg/dl) 157.55 ± 28.61 145.15 ± 34.35 0.15(b) 
Triglyceride (mg/dl)  118.59 ± 32.95 111.89 ± 29.87 0.43(b) 
Urea (mg/dl) 31.41 ± 8.02 34.33 ± 7.75 0.21( c) 
Creatinine (mg/dl) 0.87 ± 0.29 1 ± 0.28 0.08( c) 
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n = 29, (x±SD) 
HTD-2 
n = 27, (x±SD) 
P value 
NT-proBNP (pg/ml) 1603.79 ± 2114.40 7894.15 ± 9173.62 0.001*; 0.000** 
FEVK (%) 46.79 ± 13.42 33.19 ± 14.48 0.302*; 0.631** 
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Triglyceride (mg/dl)  118.59 ± 32.95 111.89 ± 29.87 0.43(b) 
Urea (mg/dl) 31.41 ± 8.02 34.33 ± 7.75 0.21( c) 
Creatinine (mg/dl) 0.87 ± 0.29 1 ± 0.28 0.08( c) 
 
 
Table 2. Mean of NT-proBNP Level and Left Ventricular Ejection Fraction 
 
 






n = 2 , (x±SD) 
HTD-2 
n = 27, (x±SD) 
P value 
NT-proBNP (pg/ml) 1603.79 ± 2114.40 7894.15 ± 9173.62 0.001*; 0.000** 
FEVK (%) 46.79 ± 13.42 33.19 ± 14.48 0.302*; 0.631** 
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Figure 1. Comparison of NT-proBNP and FEVK in HTD-1 and HTD-2 based on 
Mann Withney and Independent t tests. *p < 0.05: Mann Withney test; 

























































R = - 0.650
P<0.05
R = - 0.651
P<0.05
Figure 2. Spearman Correlation between NT-proBNP and LVEF in HTD-1 and HTD-2
A B
Figure 3. ROC NT-ProBNP in Chronic Heart failure with hypertension stage 1 
and stage 2. A. ROC of NT-proBNP; B. ROC of FEVK
Figure 1. Comparison of NT-proBNP and FEVK in HTD-1 and HTD-2 based on Mann Withney 



































Figure 1. Comparison of NT-proBNP and FEVK in HTD-1 and HTD-2 based on 
Mann Withney and Independent t tests. *p < 0.05: Mann Withney test; 
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Figure 2. Spearman Correlation between NT-proBNP and LVEF in HTD-1 and HTD-2
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Figure 3. ROC NT-ProBNP in Chronic Heart failure with hypertension stage 1 
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Figure 3. ROC NT-ProBNP in Chronic Heart failure with hypertension stage 
1 and stage 2. A. ROC of NT-proBNP; B. ROC of FEVK
Figure 2. Spearman Correlation between NT-proBNP and LVEF  in HTD-1 and HTD-2
confirms that NT-proBNP is peptide generated by 
cardiac myocytes after pressure from hypertension. 
The higher the hypertension, the higher the NT-
proBNP level is (Drewniak et al., 2015; McKie and 
Burnett, 2016; Vanderheyden et al., 2004). The results 
of  this research conform to the research conducted by 
Macheret et al. which reports difference in the mean 
of  NT-proBNP level in hypertension stage and that 
the higher the hypertension stage, the higher the NT-
proBNP level is (Macheret et al., 2012). Similarly, the 
research conducted by Ojji et al. also reports that NT-
proBNP level of  hypertension patients with heart failure 
is significantly higher than that of  hypertension patient 
without heart failure, with or without left ventricular 
hypertrophy, p<0.0001 (Ojji DB et al., 2014). However, 
the NT-proBNP increasing mechanism in hypertension 
(Figure 3A). The Cut-off-point of  left ventricular ejection 
fraction obtained is left ventricular ejection fraction of  
chronic heart failure patient with hypertension with 
area under ROC curve>0.7 and 0.746 (95% CI=0.619 
to 0.877) and p value = 0.001, showing that this left 
ventricular ejection fraction may be taken to distinguish 
hypertension stages in chronic heart failure. The Cut-
off-point of  left ventricular ejection fraction taken to 
distinguish hypertension stages in chronic heart failure 
is 39% with sensitivity of  0.67% and specificity of  0.69 
(Figure 3B).
DISCUSSION
The results of  this research show that the mean 
value of  NT-proBNP of  hypertension stage 2 group is 
higher than that of  hypertension stage 1 group. This 
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is not completely known, but this increase describes 
heart structural and functional changes. These changes 
include cardiac remodeling, left ventricle hypertrophy, 
left ventricular diastolic dysfunction and systolic 
dysfunction, and high intracardiac pressures and thus 
may be taken to detect early heart failure and to assess 
progression and prognosis of  chronic heart failure with 
hypertension. 
Hypertension causes an increase of  NT-proBNP 
through increasing left ventricular wall pressure during 
systole (increase of  left ventricular filling pressure) and 
left ventricular wall pressure during systole with left 
atrial stretch and increased left ventricular mass. This 
leads to left ventricular wall stress, which will stimulate 
NT-proBNP secretion, leading to higher blood pressure, 
higher filling pressure, higher left ventricular mass, 
and thus more NT-proBNP is released. Stimulation 
of  hormones like endothelin and angiotensin II, free 
radicals, inflammation factors like TNF-α and IL-6 as 
well as myocardial hypoxia resulted from hypertension 
will also lead to heart ventricular wall stress, which 
will increase NT-proBNP release (McKie and Burnett, 
2016; Zipes et al., 2018). 
Brain Natriuretic Peptide (BNP) and NT-
proBNP are neurohormones secreted by cardiac 
myocytes in response to heart wall stress caused by 
increased pressure and volume. Excessively increased 
pressure and volume in ventricle will stimulate BNP 
gene (Natriuretic Peptide Precursor B gene, NPPB 
gene) located at chromosome 1 and encode prehormon-
proBNP (pre-proBNP-134 amino acid peptide). Pre-
proBNP degrades to pro-BNP (108 amino acids) 
stored in secretory granules of  ventricular myocytes. 
Pro-BNP is then split by protease to BNP active form 
(77-108 amino acids) and NT-proBNP (1-76 amino 
acids) which is BNP inactive form. Brain Natriuretic 
peptide (BNP) and NT-proBNP are then released to 
circulation as hormonal counterregulation and the 
sympathetic nervous system (Fu et al., 2018; Volpe 
et al., 2016a).
The results of  this research also show that the 
mean of  left ventricular ejection fraction is lower in 
heart failure with hypertension stage 2 than that with 
hypertension stage 1. This conforms to the research 
conducted by Bielecka-dabrowa which reports that left 
ventricular ejection fraction in heart failure patient with 
hypertension is lower than that in hypertension patient 
without heart failure, p<0.0001 (Bielecka-dabrowa et 
without left ventricular hypertrophy (Kattel et al., 2016). 
Increased pressure caused by hypertension will lead to 
diastolic dysfunction with concentric left ventricular 
hypertrophy, which will cause heart failure with normal 
or increased ejection fraction, while excessive volume 
because of  hypertension will cause systolic dysfunction 
with eccentric hypertrophy, which will cause heart 
failure with decreased ejection fraction. Excessively 
increased pressure and volume will increase heart 
failure progression because of  hypertension. Other 
researches also report that a combination of  cardiac 
remodeling and increased cardiac biomarkers (NT-
proBNP) because of  hypertension may be taken to 
detect the progression of  symptomatic heart failure 
patient, particularly in heart failure with decreased 
ejection fraction (Kattel et al., 2016; Messerli et al., 
2017).
The results of  this research also show that NT-
proBNP level is strongly, negatively correlated with left 
ventricular ejection fraction in hypertension patient with 
chronic heart failure. This research result is supported 
by the research conducted by (Kang SH et al., 2015). 
which shows that heart failure patient with ejection 
fraction is kept with low NT-proBNP level compared 
to heart failure patient with decreased ejection fraction 
(Kang SH et al., 2015). This shows that increased NT-
proBNP level will decrease left ventricular ejection 
fraction. The research conducted by Ojji B, et al. also 
reports that NT-proBNP level is significantly, negatively 
correlated with left ventricular ejection fraction of  0.21 
with p value of  0.01(Ojji DB et al., 2014).
The cut-off-point value of  NT-proBNP level may 
be significantly taken to distinguish hypertension stages 
in chronic heart failure since it has area under ROC 
curve > 0.7. The cut-off-point value of  NT-proBNP 
level obtained is 1511 pg/ml with sensitivity of  0.82% 
and specificity of  0.80%. N-terminal proBNP (NT-
proBNP) may be taken to determine hypertension stage 
and prognosis of  chronic heart failure, particularly in 
in-patient and to predict the mortality of  chronic heart 
failure. NT-proBNP level based on receiver operator 
characteristic (ROC) curve of  1078 pg/ml may be 
taken to determine prognosis of  chronic heart failure 
(Gaggin and Januzzi, 2013). The cut-off-point value of  
NT-proBNP level based on ROC curve >332.5 pg/ml 
with sensitivity 0.76% and specificity of  0.95% may be 
taken to predict heart failure in hypertension patient 
(Bielecka-dabrowa et al., 2015a).
The cut-off-point value of  left ventricular ejection 
fraction may be taken to distinguish hypertension stages 
in chronic heart failure since it has area under ROC 
curve > 0.7. The cut-off-point value of  left ventricular 
al., 2015b). The research conducted by Kattel et al. also 
reports that hypertension causes concentric hypertrophy 
to hypertension group with left ventricle hypertrophy 
and concentric remodeling in hypertension patient 
10
Hilmi, et al.
• pISSN: 2085-1545 
• eISSN: 2339-093X
http://jurnal.unissula.ac.id/index.php/sainsmedika
Sains Medika, Vol. 10, No. 1, January - June 2019 : 5-11
ejection fraction obtained is 39% with sensitivity of  
0.67% and specificity of  0.69%.  This research result 
is supported by the research conducted by Volpe, et al. 
which reports that hypertension causes heart failure 
with decreased ejection fraction (<40%) because of  
excessively increased stimulation of  RAAS, SNS and 
natriuretic peptide (including NT-proBNP) and thus 
leads to left ventricular systolic dysfunction (Volpe et 
al., 2016b).
This research is limited to using secondary data 
from patients’ medical records, thus the researcher does 
not have information of  the history of  hypertension 
duration and routine treatment for the hypertension. 
In addition, there is no information of  the stages, 
duration of  sickness and treatment for chronic heart 
failure, risk factors other than patients’ diabetes 
mellitus, hypercholesterolemia, hypertriglyceridemia, 
and decreased kidney function. Therefore, further 
research is needed to examine the effects of  other than 
the abovementioned factors for better outcome.
CONCLUSION
The results of  this research show that NT-
proBNP level in hypertension stage 2 is higher than that 
in hypertension stage 1, while left ventricular ejection 
fraction in hypertension stage 2 is lower than that in 
hypertension stage 1 in chronic heart failure patient. 
The increase in NT-proBNP level will significantly 
decrease ventricular ejection fraction. The cut-off-point 
value of  NT-proBNP level and left ventricular ejection 
fraction may be taken to distinguish hypertension stages 
in chronic heart failure.  
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